Drug Profile
Research programme: LPM Leuprorelin - Soligenix
Alternative Names: LPM™ LeuprolideLatest Information Update: 18 Nov 2021
Price :
$50
*
At a glance
- Originator DOR BioPharma
- Developer Soligenix
- Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
- Mechanism of Action Gonadotropin releasing hormone inhibitors; Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Endometriosis; Prostate cancer
Most Recent Events
- 05 Jul 2013 No development reported - Preclinical for Endometriosis in USA (PO)
- 05 Jul 2013 No development reported - Preclinical for Prostate cancer in USA (PO)
- 19 May 2010 Preclinical development is ongoing in USA